NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets protein-based biosurgery and passive immunotherapy products, announced today that on July 3, 2007, the U.S. Food and Drug Administration, or FDA, approved the Company’s use of Cryoprecipitate (“cryo”) from Talecris Biotherapeutics, Inc. (“Talecris”). Cryo is a plasma fraction containing coagulation proteins and the raw material from which OMRIX manufactures BAC, the fibrinogen component of its marketed fibrin sealants, Evicel and Quixil, and Fibrin Patch product candidate.
